Von Willebrand disease

1. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysio-logy and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–2114.

2. Von Willebrand EA. Hereditar pseudohemofili. Finska Läkaresällskapets Handlingar 1926; LXVII: 87–112.

3. Blombäck M. Memories of my research into von Willebrand´s disease. Haemophilia 2012; 18: 3–6.

4. Haberichter SL. Biosyntehsis and organozation of von Willebrand factor. In: Federici AB, Lee CA, Berntorp E, et al. Von Willebrand Disease, Basic and Clinical Aspects. 1. ed. Oxford, Blackwell Publishing 2011; 7–29.

5. Borchiellini A, Fijnvandraat K, Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-Deamino-8-D-Arginine Vasopressin in humans. Blood 1996; 88: 2951–2958.

6. Vischer UM, Ingerslev J, Wollheim CB, et al. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWF:AgII) levels. Thromb Haemost 1997; 77: 387–393.

7. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160–174.

8. Van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179–185.

9. Montgomery RR, Haberichter SL. Von Willebrand factor structure and function. In: Federici AB, Lee CA, Berntorp E et al. Von Willebrand Disease, Basic and Clinical Aspects. 1. ed. Oxford, Blackwell Publishing 2011: 30–48.

10. Huck V, Schneider MF, Gorzelanny C, Schneider SW. The various states of von Willebrand factor and their function in physiology and pathophysiology. Thromb Haemost 2014; 111: 598–609.

11. Lillicrap D. The basic science, diagnosis and clinical management of von Willebrand disease. Dostupné na www: http://www.wfh.org/2/docs/Publications/VWD_WomenBleedingDisorders/TOH-35_VWD_%20Revision2008.pdf

12. Lillicrap D. Translational medicine advances in von Willebrand disease. J Thromb Haemost 2013; 11 (Suppl. 1): 75–83.

13. Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost 2001; 86: 144–148.

14. Budde U, Favaloro EJ. Laboratory diagnosis of von Willebrand dise-ase: the phenotype. In: Federici AB, Lee CA, Berntorp E et al. Von Willebrand Disease, Basic and Clinical Aspects. 1. vyd. Oxford, Blackwell Publishing 2011: 100–113.

15. Kadir RA, Economides DL, Sabin CA, et al. Variations in coagula-tion factor in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 1456–1461.

16. Knol HM, Kemperman RFJ, Kluin-Nelemans HC, et al. Haemostatic variables during normal menstrual cycle. Thromb Haemost 2012; 107: 22–29.

17. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009; 121: 71–84.

18. Budde U, Federici AB, Rand JH. Pathophysiology, epidemiology, diagnosis, and treatment of acquired von Willebrand syndrome. In: Federici AB, Lee CA, Berntorp E, et al. Von Willebrand Disease, Basic and Clinical Aspects. 1. ed. Oxford, Blackwell Publishing, 2011; 214–230.

19. Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors´ Organization. Haemophilia 2004, 10: 199-217.

20. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775–777.

21. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 774–782.

22. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171–232.

23. Quiroga T, Goycoolea M, Belmont S, et al. Quantitative impact of using different criteria for the laboratoř diagnosis of type 1 von Willebrand disease. J Thromb Haemost 2014; 12: 1238–1243.

24. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766–773.

25. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 2619–2626.

26. Tosetto A, Castaman G, Rodeghioero F. Bleeders, bleeding rates, and bleeding score. J Thromb Haemost 2013; 11(Suppl. 1): 142–150.

27. Collins PW, Cumming AM, Goodeve AC, Lillicrap D. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 2008; 14: 685–696.

28. De Maistre E, Volot F, Mourex G, et al. Performance of two new automated assays for measuring von Willebrand activity: HemosIl AcuStar and Innovance. Thromb Haemost 2014; 112: 825–830.

29. Lasne D, Dey C, Dautzenbeerg MD, et al. Screening for von Willebrand disease: contribution of an automated assay for von Willebrand factor activity. Haemophilia 2012; 18: e158–e163.

30. Reilly-Stitt C, Coppell J, Mumford AD. Discrepancy in von Willebrand factor activity determined by ristocetin cofactor and immunoturbidometric assays. Haemophilia 2014; 20: e336–e358.

31. Laffan MA, Lester W, O´Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guidelines approved by the British Committee for Standards in Haematology. British Journal of Haematology 2014; publikováno elektronicky. DOI 10.1111/bjh.13064.

32. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand‘s disease. Blood Reviews 1999; 13: 185–204.

33. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of trombocytopenie and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526–534.

34. Federici AB, Castaman G, Mannucci PM, et al. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607–621.

35. Flood VH, Gill JC, Montgomery RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. Thromb Haemost 2012 Jul; 10(7): 1425–1432, publikováno elektronicky. DOI 10.1111/j.1538-7836.2012.04746.x.

36. Flood VH, Gill JC, Friedman KD, et al. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost 2011 July; 37(5), publikováno elektronicky. DOI 10.1055/s-0031-1281039.

37. Flood VH, Friedman KD, Gill JC, et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood 2013; 121(18): 3742–3744.

38. Graf L, Moffat KA, Carlino SA, et al. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int Jnl Lab Hem 2014; 36: 341–351.

39. Grover N, Boama V, Chou MR. Pseudo (Platelet-type) von Willebrand disease in pregnancy: a case report. BMC Pregnancy and Childbirth 2013; 13: 16.

40. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat acquired von Willebrand syndrome. Blood 2011; 117(25): 6777–6785.

41. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1997-2007). Haemophilia 2008; 14 (Suppl. 1): 5–14.

42. Lethagen S, Federici AB, Castaman G. On the use of desmopressin in von Willebrand disease. In: Federici AB, Lee CA, Berntorp E, et al. Von Willebrand Disease, Basic and Clinical Aspects. 1. ed. Oxford, Blackwell Publishing 2011: 186–199.

43. Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149–153.

44. Mazurier C, Guacher Ch, Jorieux S, et al. Biological effect of desmopressin in eight patients with type 2N („Normandy“) von Willebrand disease. Br J Haematol 1994; 88: 849– 854.

45. Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology Am Soc Hematol Educ Program 2009; 113–123, publikováno elektronicky. DOI 10.1182/asheducation-2009.1.113.

46. Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors´Organization. Haemophilia 2004; 10: 218–231.

47. Ragni MV, Jankowitz RC, Jaworski K, et al. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 2011; 106: 641–645.

48. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005; 3: 2219–2227.

49. Chang AC, Rick ME, Pierce LR, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4 (suppl. 3): 1–6.

50. Kessler CM, Friedman K, Schwartz BA, et al. The pharmacokinetic diversity of two von Willebrand factor (VWF)/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Thromb Haemost 2011; 106: 279–288.

51. Nordic guidelines for diagnosis and management of von Willebrand disease – Guidelines of the Nordic Hemophilia Council – April (2008). Dostupné na www: http//www.nordhemophilia.org.

52. Mannucci PM, Franchini M, Casataman G, et al. Evidence-based recommendation on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117–126.

53. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and cafety of the factor VIII/von Willebrand factor concentrate, Haemate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224–230.

54. Lenthagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. von Willebrand factor concentrate/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elative surgery. J Thromb Haemost 2007; 5: 1420–1430.

55. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand´s disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944–951.

56. Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate, a new generation von Willebrad factor/factor VIII concentrate. Haemophilia 2009; 15: 122–130.

57. Windyga J, von Depka-Prondzinski M. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072–1079.

58. Batty P, Chen YH, Bowles L, at al. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate): a single centre experience. Haemophilia 2014; 20: 846–853.

59. Morfini M. Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter. Haemophilia 2011; 17: 846–848.

60. Borel-Derlon A, Federici AB, Roussel-Robert V. et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115–1124.

61. Berntorp E. Prophylaxis in von Willebrand disease. In: Federici AB, Lee CA, Berntorp E, et al. Von Willebrand Disease, Basic and Clinical Aspects. Oxford: Blackwell Publishing 2011: 207–213.

62. Abshire TC, Federici AB, Alvárez MT, et al. Prophylaxis in severe forms of von Willebrand´s disease: results from the Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76–81.

63. James AH, Kouides PA, Abdul-Kadir R et al. Von Willebrand disease and other bleeding disorders in women: Consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: e1–e8.

64. Pai M, Chan A, Barr R. How I manage heavy menstrual bleeding. Br J Haematol 2013; 162: 721–729.

65. Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors´ Organization. Haemophilia 2006; 12: 301–336.

66. Ramsahoye BH, Davies SV, Dasani H, et al. Obstetric management in von Willebrands disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140–144.

67. Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014; 112: 427–431.

68. Konkle BA. Von Willebrand factor and aging. Semin Thromb Hemost 2014; 40: 640–644.

69. Sohal M, Laffan M. von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol 2008; 142: 308–309.

70. Ii M, Losordo DW. Statins and the endothelium. Vascular Pharmacology 2007; 46: 1–9, publikováno elektronicky. DOI 10.1016/j.vph.2006.06.012.

71. Botero JP, Pruthi RK. Refractory bleeding from intestinal angiodysplasias successfully treated with danazol in free patients with von Willebrand disease. Blood Coagul Fibrinolysis 2013; 24: 884–886.

72. Pergantou H, Xafaki P, Adamtziki E, et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia 2012; 18(3): e66–e67.